Acne inversa: research on pathogenesis and preclinical testing of potential therapeutic approaches

Recruiting

• Conditions: healthy control participants; L73.2; L40; L20; L44.0; L80; L43; Hidradenitis suppurativa; Psoriasis; Atopic dermatitis

• Registration Number: DRKS00028958
• Lead Sponsor: Charité Universitätsmedizin Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1260

Inclusion Criteria

patients with Acne inversa, other chronic inflammatory skin diseases or healthy participants respectively
- age: = 18 years
- blood Hb > 10 g/dl (exept if residual material obtained from excision surgery or diagnostic biopsies is used)
- willingness to comply with study procedures (taking of skin biopsies)
- written, informed consent was given

Exclusion Criteria

- age: <18 years,
- persons, who are not able to give wrtitten informed consent,
- pregnancy or breast feeding,
- intake of medication that influences blood ,coagulation the last 10 days before the planned procedures (taking of blood or skin samples),
- known allergies against local anesthesia, patches or latex/gloves,
- known acute or chronic infectious diseases (e.g. influenza, HIV, HCV, HBV, Covid-19
- known malignancies,
- anamnestic hints to exuberant formation of scars or keloids,
- person, who are in the physician´s view not able to fulfill the study requirements.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoints of the study are:<br><br>1) Identification and characterization of the molecular and cellular features contributing to the development and persitence of skin alterations of Acne inversa patients.<br><br>2) Testing of novel therapeutic approaches using skin model systems of Acne inversa.

Secondary Outcome Measures

Name	Time	Method
Main secondary endpoints of the study are:<br><br>1) identification of molecular and cellular differences between lesional versus non-lesional skin of Acne inversa patients,<br>2) identification of molecular and cellular differences between non-lesional skin of Acne inversa patients versus skin of healthy participants,<br>3) identification of molecular and cellular differences between lesional skin of Acne inversa patients versus skin of healthy participants,<br>4) identification of molecular and cellular differences between lesional / non-lesional skin of Acne inversa patients and those of other chronic inflammatory skin diseases<br>5) correlation of molecular and cellular features of lesional / non-lesional skin of patients among each other and with anamnestic, demopraphic, physiological and clinical data of the patients,<br>6) characterization of penetration depth of neutralizing /inhibiting substances (e.g. antibodies) in ex vivo cultivated skin models.